Xeltis aXess Vascular Access Device for Hemodialysis Launched in Europe

July 15, 2026—Xeltis announced the official start of the European commercialization of aXess vascular access device for patients requiring hemodialysis.

Delcath Commences DELUMA Trial of Hepzato in Liver-Dominant Metastatic Breast Cancer

July 14, 2026—Delcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announced that the first patient has been dosed at the European Institute of Oncology in Milan, Italy, in a global phase 2 clinical trial evaluating the company’s Hepzato in combination with standard of care (SOC) treatment for liver-dominant metastatic breast cancer (mBC).

Vesalio Appoints Greg Cook as Chief Commercial Officer

July 14, 2026—Vesalio announced the appointment of Greg Cook as Chief Commercial Officer, responsible for leading the company’s commercial strategy, market development, sales, marketing, and commercial operations.

Immediate Adoption of Enhanced Radiation Protection in Catheterization Labs Recommended in Multisociety Statement

July 14, 2026—The Society for Cardiovascular Angiography and Interventions (SCAI) announced that a multisociety expert consensus statement on radiation protection in catheterization labs was published by David G. Rizik, MD, et al in JSCAI.

Fluidx’s GPX Embolic Device Meets Primary Endpoints in Pivotal Trial

July 14, 2026—Fluidx Medical Technology, Inc. announced results from a pivotal clinical trial evaluating the company’s GPX embolic device.

HistoSonics’ Edison Histotripsy System Receives CE Mark Approval

July 13, 2026—HistoSonics announced that it has received approval in Europe for its Edison system, enabling the commercialization of the company’s histotripsy technology in Europe and other markets that recognize the CE Mark.

Stereotaxis Completes Acquisition of Robocath

July 13, 2026—Stereotaxis announced that it has completed its previously announced acquisition of Robocath, a Rouen, France-based developer of robotic technologies for interventional cardiology and neurointerventions.

GLP-1 RAs Linked to Lower Mortality, Amputation Risk in PAD and Type 2 Diabetes

July 6, 2026—Glucagon‐like peptide‐1 receptor agonists (GLP-1 RAs) were shown to be associated with lower risks of death, hospitalization, amputation, and lower-extremity revascularization compared with metformin among adults with type 2 diabetes and peripheral artery disease (PAD), according to the American Heart Association.